Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

Abstract Background Neoadjuvant immunotherapy targeting immune checkpoint programmed death-1 (PD-1) is under investigation in various tumour settings including non-small-cell lung cancer (NSCLC). Preclinical models demonstrate the superior power of the immunotherapy provided in a neoadjuvant (pre-op...

Full description

Bibliographic Details
Main Authors: Elizabeth Ahern, Annette Cubitt, Emma Ballard, Michele W. L. Teng, William C. Dougall, Mark J. Smyth, David Godbolt, Rishendran Naidoo, Amanda Goldrick, Brett G. M. Hughes
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Trials
Subjects:
NSCLC
Lung cancer
Immunotherapy
RANKL
Denosumab
PD1
Online Access:https://doi.org/10.1186/s13063-019-3951-x

Internet

https://doi.org/10.1186/s13063-019-3951-x

Similar Items